Roche says Alecensa helps keep ALK-positive lung cancer at bay after surgery as it looks to expand label

Roche’s alectinib, marketed as Alecensa, helped certain lung cancer patients stay disease-free for longer following surgery in a Phase III study, the big pharma announced Friday.

Roche’s subsidiary Genentech tested the drug in a Phase III open-label study with 257 patients with ALK-positive non-small cell lung…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks